Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD

Journal of the American Society of Nephrology

Volumn 20, Issue 12, 2009, Pages 2651-2660

  Eckardt, Kai Uwe ^a   Scherhag, Armin ^b,c   Macdougall, Iain C ^d   Tsakiris, Dimitrios ^e   Clyne, Naomi ^f   Locatelli, Francesco ^g   Zaug, Michael F ^b   Burger, Hans U ^b   Drueke, Tilman B ^h  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d KING S COLLEGE HOSPITAL   (United Kingdom)

^e GENERAL HOSPITAL OF VERIA   (Greece)

^f LUND UNIVERSITY HOSPITAL   (Sweden)

^g A MANZONI HOSPITAL   (Italy)

^h HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE COURSE; ECHOCARDIOGRAPHY; EVENT FREE SURVIVAL; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL;

EID: 72049089062     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2009060631     Document Type: Article

References (44)

1. Schiffrin EL, Lipman ML, Mann JF: Chronic kidney disease: Effects on the cardiovascular system. Circulation 116: 85-97, 2007 (Pubitemid 47016250)
2. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE: Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 47: 186-192, 1995
3. Levin A, Singer J, Thompson CR, Ross H, Lewis M: Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. Am J Kidney Dis 27: 347-354, 1996 (Pubitemid 26075843)
4. Nardi E, Palermo A, Mulè G, Cusimano P, Cottone S, Cerasola G: Left ventricular hypertrophy and geometry in hypertensive patients with chronic kidney disease. J Hypertens 27: 633-641, 2009
5. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE: Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant 11: 1277-1285, 1996 (Pubitemid 26241416)
6. London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, Metivier F, Adda H, Safar ME: Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: Follow-up of an interventional study. J Am Soc Nephrol 12: 2759-2767, 2001 (Pubitemid 33115424)
7. Kessler M, Zannad F, Lehert P, Grünfeld JP, Thuilliez C, Leizorovicz A, Lechat P, FOSIDIAL Investigators: Predictors of cardiovascular events in patients with end-stage renal disease: An analysis from the Fosinopril in dialysis study. Nephrol Dial Transplant 22: 3573-3579, 2007 (Pubitemid 350212486)
8. Silberberg JS, Barre PE, Prichard SS, Sniderman AD: Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 36: 286-290, 1989 (Pubitemid 19202488)
9. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 28: 53-61, 1996 (Pubitemid 26231466)
10. Silberberg J, Racine N, Barre P, Sniderman AD: Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin. Can J Cardiol 6: 1-4, 1990 (Pubitemid 20132367)
11. Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, Burgess E, Jindal K, Barrett B, Singer J, Djurdjev O: Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 34: 125-134, 1999 (Pubitemid 29318806)
12. O'Meara E, Clayton T, McEntegart MB, McMurray JJ, Lang CC, Roger SD, Young JB, Solomon SD, Granger CB, Ostergren J, Olofsson B, Michelson EL, Pocock S, Yusuf S, Swedberg K, Pfeffer MA, CHARM Committees and Investigators: Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: Results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation 113: 986-994, 2006 (Pubitemid 43879474)
13. Weiner DE, Tighiouart H, Vlagopoulos PT, Griffith JL, Salem DN, Levey AS, Sarnak MJ: Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J Am Soc Nephrol 16: 1803-1810, 2005
14. Eckardt KU: Cardiovascular consequences of renal anaemia and erythropoietin therapy. Nephrol Dial Transplant 14: 1317-1323, 1999
15. London GM, Zins B, Pannier B, Naret C, Berthelot JM, Jacquot C, Safar M, Drueke TB: Vascular changes in hemodialysis patients in response to recombinant human erythropoietin. Kidney Int 36: 878-882, 1989 (Pubitemid 19283287)
16. Macdougall IC, Lewis NP, Saunders MJ, Cochlin DL, Davies ME, Hutton RD, Fox KA, Coles GA, Williams JD: Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. Lancet 335: 489-493, 1990 (Pubitemid 20073052)
17. Sikole A, Polenakovic M, Spirovska V, Polenakovic B, Masin G: Analysis of heart morphology and function following erythropoietin treatment of anemic dialysis patients. Artif Organs 17: 977-984, 1993 (Pubitemid 24025978)
18. Portolés J, Torralbo A, Martin P, Rodrigo J, Herrero JA, Barrientos A: Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 29: 541-548, 1997 (Pubitemid 27155274)
19. Foley RN, Parfrey PS, Morgan J, Barré PE, Campbell P, Cartier P, Coyle D, Fine A, Handa P, Kingma I, Lau CY, Levin A, Mendelssohn D, Muirhead N, Murphy B, Plante RK, Posen G, Wells GA: Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 58: 1325-1335, 2000 (Pubitemid 30678057)
20. Roger SD, McMahon LP, Clarkson A, Disney A, Harris D, Hawley C, Healy H, Kerr P, Lynn K, Parnham A, Pascoe R, Voss D, Walker R, Levin A: Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): Results of a randomised clinical trial. J Am Soc Nephrol 15: 148-156, 2004 (Pubitemid 38020706)
21. Levin A, Djurdjev O, Thompson CR, Barrett B, Ethier J, Carlisle E, Barre P, Magner P, Muirhead N, Tobe S, Tam P, Wadgymar JA, Kappel J, Holland D, Pichette V, Shoker A, Soltys G, Verrelli M, Singer J: Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 46: 799-811, 2005 (Pubitemid 41505453)
22. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D: Double-blind comparison of full and partial anaemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 16: 2180-2189, 2005
23. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A, CREATE Investigators: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071-2084, 2006 (Pubitemid 44749316)
24. Macdougall I, Temple RM, Kwan J: Is early treatment of anaemia with epoetin alfa beneficial to predialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomised, comparative group trial. Nephrol Dial Transplant 22: 784-793, 2007 (Pubitemid 46351686)
25. Ritz E, Laville M, Bilous RW, O'Donoghue D, Scherhag A, Burger U, de Alvaro F: Anemia Correction in Diabetes Study Investigators: Target level for hemoglobin correction in patients with diabetes and CKD: Primary results of the Anemia Correction in Diabetes (ACORD) Study [erratum appears in Am J Kidney Dis 49: 562, 2007]. Am J Kidney Dis 49: 194-207, 2007
26. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098, 2006 (Pubitemid 44749317)
27. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584-590, 1998 (Pubitemid 28385655)
28. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barré PE: The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 5: 2024-2031, 1995
29. Parfrey PS, Lauve M, Latremouille-Viau D, Lefebvre P: Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: A meta-analysis. Clin J Am Soc Nephrol 4: 755-762, 2009
30. Hunter JJ, Chien KR: Signaling pathways for cardiac hypertrophy and failure. N Engl J Med 341: 1276-1283, 1999 (Pubitemid 29489744)
31. Selvetella G, Lembo G: Mechanisms of cardiac hypertrophy. Heart Fail Clin 1: 263-273, 2005
32. Zoccali C: How important is echocardiography for risk stratification in follow-up of patients with chronic kidney disease? Nat Clin Pract Nephrol 3: 178-179, 2007 (Pubitemid 46496865)
33. Mark PB, Patel RK, Jardine AG: Are we overestimating left ventricular abnormalities in end-stage renal disease? Nephrol Dial Transplant 22: 1815-1819, 2007
34. Rigatto C, Foley RN, Kent GM, Guttmann R, Parfrey PS: Long-term changes in left ventricular hypertrophy after renal transplantation. Transplantation 70: 570-575, 2000 (Pubitemid 30659638)
35. Zolty R, Hynes PJ, Vittorio TJ: Severe left ventricular systolic dysfunction may reverse with renal transplantation: Uremic cardiomyopathy and cardiorenal syndrome. Am J Transplant 8: 2219-2224, 2008
36. Lundby C, Thomsen JJ, Boushel R, Koskolou M, Warberg J, Calbet JA, Robach P: Erythropoietin treatment elevates haemoglobin concentration by increasing red cell volume and depressing plasma volume. J Physiol 578: 309-314, 2007 (Pubitemid 44971127)
37. Abraham PA, Opsahl JA, Keshaviah PR, Collins AJ, Whalen JJ, Asinger RW, McLain LA, Hanson G, Davis MG, Halstenson CE: Body fluid spaces and blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. Am J Kidney Dis 16: 438-446, 1990
38. Lebel M, Kingma I, Grose JH, Langlois S: Hemodynamic and hormonal changes during erythropoietin therapy in hemodialysis patients. J Am Soc Nephrol 9: 97-104, 1998 (Pubitemid 28050050)
39. Anastassiades E, Howarth D, Howarth J, Shanks D, Waters H, Hyde K, Yin JL, Geary C, Gokal R: Influence of blood volume on the blood pressure of predialysis and peritoneal dialysis patients treated with erythropoietin. Nephrol Dial Transplant 8: 621-625, 1993 (Pubitemid 23231145)
40. Macdougall IC, Hutton RD, Coles GA, Williams JD: The use of erythropoietin in renal failure. Postgrad Med J 67: 9-15, 1991
41. Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, Patel UD, Singh AK: Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 74: 791-798, 2008
42. Eckardt K-U: The CREATE trial: Building the evidence. Nephrol Dial Transplant 16[Suppl 2]: 16-18, 2001
43. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I: Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr 2: 358-367, 1989
44. Huwez FU, Pringle SD, Macfarlane PW: A new classification of left ventricular geometry in patients with cardiac disease based on M-mode echocardiography. Am J Cardiol 70: 681-688, 1992